REVX.F Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €30.80 |
| 52 Week High | €38.89 |
| 52 Week Low | €28.35 |
| Beta | 1.34 |
| 11 Month Change | -20.80% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2,510.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| REVX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 0.3% |
| 1Y | n/a | 21.4% | 31.1% |
Return vs Industry: Insufficient data to determine how REVX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how REVX.F performed against the US Market.
Price Volatility
| REVX.F volatility | |
|---|---|
| REVX.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: REVX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine REVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 230 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, rest of Europe, North America, and internationally. The company offers iCare IC100 and IC200 tonometers; iCare HOME, a device for self-measurement of eye pressure; and iCare TONOVET an IOP measuring on animal patients by general veterinary practitioners, veterinary ophthalmologists, and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON AF, a device with confocal retinal imaging; and DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| REVX.F fundamental statistics | |
|---|---|
| Market cap | US$774.46m |
| Earnings (TTM) | US$20.03m |
| Revenue (TTM) | US$107.43m |
38.7x
P/E Ratio7.2x
P/S RatioIs REVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REVX.F income statement (TTM) | |
|---|---|
| Revenue | €102.49m |
| Cost of Revenue | €30.34m |
| Gross Profit | €72.14m |
| Other Expenses | €53.04m |
| Earnings | €19.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.72 |
| Gross Margin | 70.39% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 11.7% |
How did REVX.F perform over the long term?
See historical performance and comparison